vs
Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and GRAIL, Inc. (GRAL). Click either name above to swap in a different company.
EXACT SCIENCES CORP is the larger business by last-quarter revenue ($878.4M vs $43.6M, roughly 20.1× GRAIL, Inc.). EXACT SCIENCES CORP runs the higher net margin — -9.8% vs -227.5%, a 217.7% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 14.0%). EXACT SCIENCES CORP produced more free cash flow last quarter ($120.4M vs $-63.9M). Over the past eight quarters, GRAIL, Inc.'s revenue compounded faster (27.7% CAGR vs 17.4%).
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
EXAS vs GRAL — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $878.4M | $43.6M |
| Net Profit | $-86.0M | $-99.2M |
| Gross Margin | 70.1% | — |
| Operating Margin | -9.4% | -285.4% |
| Net Margin | -9.8% | -227.5% |
| Revenue YoY | 23.1% | 14.0% |
| Net Profit YoY | 90.1% | -2.2% |
| EPS (diluted) | $-0.45 | $-2.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $878.4M | $43.6M | ||
| Q3 25 | $850.7M | $36.2M | ||
| Q2 25 | $811.1M | $35.5M | ||
| Q1 25 | $706.8M | $31.8M | ||
| Q4 24 | $713.4M | $38.3M | ||
| Q3 24 | $708.7M | $28.7M | ||
| Q2 24 | $699.3M | $32.0M | ||
| Q1 24 | $637.5M | $26.7M |
| Q4 25 | $-86.0M | $-99.2M | ||
| Q3 25 | $-19.6M | $-89.0M | ||
| Q2 25 | $-1.2M | $-114.0M | ||
| Q1 25 | $-101.2M | $-106.2M | ||
| Q4 24 | $-864.6M | $-97.1M | ||
| Q3 24 | $-38.2M | $-125.7M | ||
| Q2 24 | $-15.8M | $-1.6B | ||
| Q1 24 | $-110.2M | $-218.9M |
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
| Q4 25 | -9.4% | -285.4% | ||
| Q3 25 | -3.0% | -346.2% | ||
| Q2 25 | -0.3% | -446.9% | ||
| Q1 25 | -13.6% | -482.5% | ||
| Q4 24 | -122.8% | -358.0% | ||
| Q3 24 | -5.6% | -640.5% | ||
| Q2 24 | -3.8% | -5133.8% | ||
| Q1 24 | -16.7% | -851.1% |
| Q4 25 | -9.8% | -227.5% | ||
| Q3 25 | -2.3% | -245.8% | ||
| Q2 25 | -0.1% | -320.7% | ||
| Q1 25 | -14.3% | -333.6% | ||
| Q4 24 | -121.2% | -253.8% | ||
| Q3 24 | -5.4% | -438.7% | ||
| Q2 24 | -2.3% | -4958.8% | ||
| Q1 24 | -17.3% | -819.3% |
| Q4 25 | $-0.45 | $-2.37 | ||
| Q3 25 | $-0.10 | $-2.46 | ||
| Q2 25 | $-0.01 | $-3.18 | ||
| Q1 25 | $-0.54 | $-3.10 | ||
| Q4 24 | $-4.69 | $-1.49 | ||
| Q3 24 | $-0.21 | $-3.94 | ||
| Q2 24 | $-0.09 | $-51.06 | ||
| Q1 24 | $-0.60 | $-7.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $964.7M | $249.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.4B | $2.6B |
| Total Assets | $5.9B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $964.7M | $249.7M | ||
| Q3 25 | $1.0B | $126.9M | ||
| Q2 25 | $858.4M | $127.4M | ||
| Q1 25 | $786.2M | $133.9M | ||
| Q4 24 | $1.0B | $214.2M | ||
| Q3 24 | $1.0B | $853.6M | ||
| Q2 24 | $946.8M | $958.8M | ||
| Q1 24 | $652.1M | $199.7M |
| Q4 25 | $2.4B | $2.6B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.4B | $2.4B | ||
| Q4 24 | $2.4B | $2.5B | ||
| Q3 24 | $3.2B | $2.6B | ||
| Q2 24 | $3.2B | $2.7B | ||
| Q1 24 | $3.1B | — |
| Q4 25 | $5.9B | $2.9B | ||
| Q3 25 | $5.9B | $2.6B | ||
| Q2 25 | $5.8B | $2.7B | ||
| Q1 25 | $5.7B | $2.8B | ||
| Q4 24 | $5.9B | $3.0B | ||
| Q3 24 | $6.7B | $3.1B | ||
| Q2 24 | $6.7B | $3.3B | ||
| Q1 24 | $6.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $151.7M | $-63.8M |
| Free Cash FlowOCF − Capex | $120.4M | $-63.9M |
| FCF MarginFCF / Revenue | 13.7% | -146.5% |
| Capex IntensityCapex / Revenue | 3.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.8M | $-299.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $151.7M | $-63.8M | ||
| Q3 25 | $219.9M | $-63.2M | ||
| Q2 25 | $89.0M | $-77.0M | ||
| Q1 25 | $30.8M | $-95.0M | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $-104.6M | ||
| Q2 24 | $107.1M | $-171.8M | ||
| Q1 24 | $-82.3M | $-207.3M |
| Q4 25 | $120.4M | $-63.9M | ||
| Q3 25 | $190.0M | $-63.6M | ||
| Q2 25 | $46.7M | $-77.3M | ||
| Q1 25 | $-365.0K | $-95.1M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | $-105.6M | ||
| Q2 24 | $71.2M | $-173.2M | ||
| Q1 24 | $-120.0M | $-209.8M |
| Q4 25 | 13.7% | -146.5% | ||
| Q3 25 | 22.3% | -175.8% | ||
| Q2 25 | 5.8% | -217.6% | ||
| Q1 25 | -0.1% | -298.6% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | -368.4% | ||
| Q2 24 | 10.2% | -541.7% | ||
| Q1 24 | -18.8% | -785.3% |
| Q4 25 | 3.6% | 0.2% | ||
| Q3 25 | 3.5% | 1.1% | ||
| Q2 25 | 5.2% | 1.0% | ||
| Q1 25 | 4.4% | 0.2% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | 3.4% | ||
| Q2 24 | 5.1% | 4.3% | ||
| Q1 24 | 5.9% | 9.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
GRAL
| Screening Revenue | $42.3M | 97% |
| Developmental Services Revenue | $1.3M | 3% |
